Recent Updates — EVMN
Evommune, Inc. presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the European Academy of Dermatology and Venereology Congress on October 1, 2026. The trial met its primary endpoint with a 55% least-squares mean reduction in EASI scores versus 22% for placebo (p<0.01) at Week 12. Biomarker analyses confirmed robust Th2 pathway modulation and broad anti-inflammatory activity across Th1, Th17/22 pathways. The company plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027. Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.
On September 8, 2026, Evommune announced that its Phase 2b trial of EVO756 for moderate-to-severe atopic dermatitis failed to meet primary and secondary endpoints across all studied doses. Consequently, the company will cease development of EVO756 in this indication but will continue evaluating it for migraine prophylaxis. The firm also noted that its lead AD program, EVO301, is advancing toward a Phase 2b trial planned for mid-2027 following positive Phase 2a data. Evommune expects current cash and investments to fund operations into 2029. Evommune operates in the biotechnology industry, developing innovative therapies targeting chronic inflammatory diseases.
Evommune announced the dosing of the first patient in a Phase 2b clinical trial for EVO756, an oral MRGPRX2 inhibitor intended for migraine prophylaxis. The global, randomized study will enroll approximately 330 adults with refractory migraine across two active dose arms and placebo for 12 weeks, exploring daily doses up to 100 mg. Top-line data is expected in 2027. Evommune operates as a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases.
Evommune, Inc. announced on June 29, 2026, that its Phase 2b trial for EVO756 in treating moderate-to-severe chronic spontaneous urticaria (CSU) failed to meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks across all dose regimens. Consequently, the Company plans to cease development of EVO756 for the CSU indication. Evommune, Inc. is a biotechnology company focused on developing immune-mediated disease treatments.